Wellgistics Health Executives Exercise 200,000 Warrants
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 30 2026
0mins
Wellgistics Health announced that its Executive Chairman Suren Ajjarapu and President & Interim Co-CEO Prashant Patel have exercised all warrants previously issued to them in connection with the conversion of their outstanding salaries into common shares at $10 per share. The exercise of the warrants resulted in the issuance of a total of 200,000 to the executives. Following the exercise of these warrants, Wellgistics confirms that as of the date of this press release there are 2,847,198 common shares outstanding. Certain stockholders holding approximately 1,533,930 common shares, representing a majority of the outstanding common shares, have entered into lock-up agreements that preclude the sale of their shares into the market for at least ninety days from today's date.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WGRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WGRX
About WGRX
Wellgistics Health, Inc. is a holding company, which conducts business through two wholly owned subsidiaries, Wood Sage, LLC and Wellgistics LLC and two indirect subsidiaries, Alliance Pharma Solutions, LLC and Community Specialty Pharmacy, LLC. It focuses on specialty medications and a community-based model offering home delivery services to patients. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. Its technology platform, DelivMeds, serves as a pharmacy hub and allows for clinical services to be connected to the Company’s health pharmacy operations. This platform will allow for an end-to-end mobile application solution whereby patients can digitize their prescription journey. The solution helps to preserve patient autonomy, improve prescription price transparency, and provide additional concierge services. Its products include Kyzatrex and Semaglutide and Tirzepatide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Stocks Show Significant Pre-Market Activity
- Significant Pre-Market Gains: Wellgistics Health, Inc. (WGRX) surged 29% to $4.05 in pre-market trading, indicating strong market confidence in its future growth, which may attract more investor interest.
- Other Gainers: Co-Diagnostics, Inc. (CODX) rose 11% to $8.12, while Palladyne AI Corp. (PDYN) increased 10% to $8.21, reflecting an overall positive sentiment in the biotech sector that could drive investment momentum.
- Pre-Market Decliners: AIM ImmunoTech Inc. (AIM) fell 21% to $0.32, highlighting market concerns about its outlook, which may lead investors to reassess their strategies.
- Additional Decliners: BioRestorative Therapies, Inc. (BRTX) dropped 20% to $1.30, and Aditxt, Inc. (ADTX) decreased 18% to $0.17, indicating a lack of confidence in certain biotech companies, potentially impacting their fundraising capabilities.
See More
Wellgistics Health Approves 1-for-50 Reverse Stock Split
- Reverse Stock Split Plan: Wellgistics Health is set to implement a 1-for-50 reverse stock split on May 26, 2026, aimed at increasing the per-share trading price to comply with Nasdaq's minimum bid requirements, thereby enhancing the company's market compliance.
- Share Impact: The reverse split will reduce outstanding shares from approximately 125.7 million to 2.5 million, while the total authorized shares remain unchanged; proportional adjustments will be made to outstanding options, warrants, and convertible securities to protect investor interests.
- Market Performance Review: WGRX shares have traded between $0.07 and $2.56 over the past year, closing at $0.12, down 23.12%, and further declining 24.65% in pre-market trading, indicating a negative market reaction to the split announcement.
- Company Background: Wellgistics integrates its proprietary AI platform EinsteinRx with its blockchain-enabled PharmacyChain system to optimize prescription drug dispensing, connecting over 6,500 pharmacies and 200 manufacturers, showcasing its innovative capabilities in the health information technology sector.
See More
Wellgistics Health Announces 1-for-50 Reverse Stock Split
- Reverse Stock Split Plan: Wellgistics Health has announced a 1-for-50 reverse stock split effective May 26, 2026, aimed at increasing the per-share trading price to meet Nasdaq's minimum bid price requirement, thereby ensuring continued listing on the exchange.
- Shareholder Approval: The plan received formal approval from the company's Board of Directors and a majority of voting stockholders on April 2, 2026, reflecting shareholder support and confidence in the company's strategic adjustments.
- Impact on Shares: Following the reverse split, the number of outstanding shares will decrease from approximately 125.67 million to around 2.51 million, while the authorized share capital remains unchanged, ensuring proportional adjustments for all shareholders.
- Automatic Adjustment Mechanism: Shareholders holding shares in book-entry form will not need to take any action, as adjustments will also be made automatically for those with shares through brokers or nominees, ensuring that shareholder rights are preserved post-split.
See More
Wellgistics Announces 1-for-50 Reverse Stock Split
- Reverse Split Announcement: Wellgistics Health, Inc. will implement a 1-for-50 reverse stock split on May 26, 2026, aimed at increasing the per-share trading price to meet Nasdaq's minimum bid price requirement, thereby ensuring continued listing compliance.
- Shareholder Approval: The reverse split plan was approved by a majority of shareholders on April 2, 2026, and is expected to reduce the outstanding shares from approximately 126.7 million to about 2.5 million, significantly decreasing the market float.
- No Action Required for Shareholders: Shareholders holding shares in electronic book-entry form will not need to take any action, as their holdings will be automatically adjusted, simplifying the process and reducing operational complexity for investors.
- Future Growth Strategy: The reverse split aligns with Wellgistics' strategy of integrating its AI platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™, aiming to enhance its competitive position in the health information technology sector.
See More
Formation of DelivMeds AI with Approximate Asset Value of $4 Billion
- Asset Value: The formation of DelivMeds AI is expected to have an approximate asset value of $4 billion, stemming from a comprehensive partnership between Datavault AI and Wellgistics Health aimed at enhancing healthcare service efficiency through blockchain and AI integration, thereby securing a competitive edge in the rapidly evolving healthcare market.
- Technology Integration and Expansion: The fully binding term sheet signed between Datavault AI and Wellgistics Health expands the PharmacyChain™ platform to include Healthcare-as-a-Service (HaaS), connecting over 6,500 pharmacies and 200 manufacturers, significantly improving the efficiency and transparency of pharmaceutical delivery.
- Innovative Healthcare Solutions: Following the acquisition of the QOLPOM patent portfolio, DelivMeds AI will leverage biometric verification and AI-driven drones to enhance pharmaceutical delivery and sample collection in rural areas, which is expected to greatly improve accessibility and compliance in healthcare services.
- Market Promotion and Collaboration: The
See More
Wellgistics Health Reports Q1 Loss and $105M Acquisition Intent
- Q1 Loss: Wellgistics Health reported a GAAP EPS of -$0.07 for Q1, indicating challenges in profitability that may affect investor confidence and lead to stock price volatility.
- Acquisition Intent: The company has signed a Letter of Intent to explore a $105 million acquisition of Neuritek, aiming to enhance its competitiveness by expanding its product line and market share.
- Strategic Implications: If successful, this acquisition could allow Wellgistics Health to enter new market segments, strengthening its position in the health technology sector and laying the groundwork for future growth.
- Market Reaction: While the Q1 loss may negatively impact stock prices, the announcement of the acquisition intent could attract investor interest, enhancing market expectations for the company's long-term development.
See More
Biotech Stocks Show Significant Pre-Market Activity
- Significant Pre-Market Gains: Wellgistics Health, Inc. (WGRX) surged 29% to $4.05 in pre-market trading, indicating strong market confidence in its future growth, which may attract more investor interest.
- Other Gainers: Co-Diagnostics, Inc. (CODX) rose 11% to $8.12, while Palladyne AI Corp. (PDYN) increased 10% to $8.21, reflecting an overall positive sentiment in the biotech sector that could drive investment momentum.
- Pre-Market Decliners: AIM ImmunoTech Inc. (AIM) fell 21% to $0.32, highlighting market concerns about its outlook, which may lead investors to reassess their strategies.
- Additional Decliners: BioRestorative Therapies, Inc. (BRTX) dropped 20% to $1.30, and Aditxt, Inc. (ADTX) decreased 18% to $0.17, indicating a lack of confidence in certain biotech companies, potentially impacting their fundraising capabilities.
See More
Wellgistics Health Approves 1-for-50 Reverse Stock Split
- Reverse Stock Split Plan: Wellgistics Health is set to implement a 1-for-50 reverse stock split on May 26, 2026, aimed at increasing the per-share trading price to comply with Nasdaq's minimum bid requirements, thereby enhancing the company's market compliance.
- Share Impact: The reverse split will reduce outstanding shares from approximately 125.7 million to 2.5 million, while the total authorized shares remain unchanged; proportional adjustments will be made to outstanding options, warrants, and convertible securities to protect investor interests.
- Market Performance Review: WGRX shares have traded between $0.07 and $2.56 over the past year, closing at $0.12, down 23.12%, and further declining 24.65% in pre-market trading, indicating a negative market reaction to the split announcement.
- Company Background: Wellgistics integrates its proprietary AI platform EinsteinRx with its blockchain-enabled PharmacyChain system to optimize prescription drug dispensing, connecting over 6,500 pharmacies and 200 manufacturers, showcasing its innovative capabilities in the health information technology sector.
See More
Wellgistics Health Announces 1-for-50 Reverse Stock Split
- Reverse Stock Split Plan: Wellgistics Health has announced a 1-for-50 reverse stock split effective May 26, 2026, aimed at increasing the per-share trading price to meet Nasdaq's minimum bid price requirement, thereby ensuring continued listing on the exchange.
- Shareholder Approval: The plan received formal approval from the company's Board of Directors and a majority of voting stockholders on April 2, 2026, reflecting shareholder support and confidence in the company's strategic adjustments.
- Impact on Shares: Following the reverse split, the number of outstanding shares will decrease from approximately 125.67 million to around 2.51 million, while the authorized share capital remains unchanged, ensuring proportional adjustments for all shareholders.
- Automatic Adjustment Mechanism: Shareholders holding shares in book-entry form will not need to take any action, as adjustments will also be made automatically for those with shares through brokers or nominees, ensuring that shareholder rights are preserved post-split.
See More
Wellgistics Announces 1-for-50 Reverse Stock Split
- Reverse Split Announcement: Wellgistics Health, Inc. will implement a 1-for-50 reverse stock split on May 26, 2026, aimed at increasing the per-share trading price to meet Nasdaq's minimum bid price requirement, thereby ensuring continued listing compliance.
- Shareholder Approval: The reverse split plan was approved by a majority of shareholders on April 2, 2026, and is expected to reduce the outstanding shares from approximately 126.7 million to about 2.5 million, significantly decreasing the market float.
- No Action Required for Shareholders: Shareholders holding shares in electronic book-entry form will not need to take any action, as their holdings will be automatically adjusted, simplifying the process and reducing operational complexity for investors.
- Future Growth Strategy: The reverse split aligns with Wellgistics' strategy of integrating its AI platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™, aiming to enhance its competitive position in the health information technology sector.
See More
Formation of DelivMeds AI with Approximate Asset Value of $4 Billion
- Asset Value: The formation of DelivMeds AI is expected to have an approximate asset value of $4 billion, stemming from a comprehensive partnership between Datavault AI and Wellgistics Health aimed at enhancing healthcare service efficiency through blockchain and AI integration, thereby securing a competitive edge in the rapidly evolving healthcare market.
- Technology Integration and Expansion: The fully binding term sheet signed between Datavault AI and Wellgistics Health expands the PharmacyChain™ platform to include Healthcare-as-a-Service (HaaS), connecting over 6,500 pharmacies and 200 manufacturers, significantly improving the efficiency and transparency of pharmaceutical delivery.
- Innovative Healthcare Solutions: Following the acquisition of the QOLPOM patent portfolio, DelivMeds AI will leverage biometric verification and AI-driven drones to enhance pharmaceutical delivery and sample collection in rural areas, which is expected to greatly improve accessibility and compliance in healthcare services.
- Market Promotion and Collaboration: The
See More
Wellgistics Health Reports Q1 Loss and $105M Acquisition Intent
- Q1 Loss: Wellgistics Health reported a GAAP EPS of -$0.07 for Q1, indicating challenges in profitability that may affect investor confidence and lead to stock price volatility.
- Acquisition Intent: The company has signed a Letter of Intent to explore a $105 million acquisition of Neuritek, aiming to enhance its competitiveness by expanding its product line and market share.
- Strategic Implications: If successful, this acquisition could allow Wellgistics Health to enter new market segments, strengthening its position in the health technology sector and laying the groundwork for future growth.
- Market Reaction: While the Q1 loss may negatively impact stock prices, the announcement of the acquisition intent could attract investor interest, enhancing market expectations for the company's long-term development.
See More
